272 related articles for article (PubMed ID: 32815757)
1. Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes.
Dow ER; Yung M; Tsui E
Ocul Immunol Inflamm; 2021 Jan; 29(1):203-211. PubMed ID: 32815757
[No Abstract] [Full Text] [Related]
2. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition.
Sun MM; Levinson RD; Filipowicz A; Anesi S; Kaplan HJ; Wang W; Goldstein DA; Gangaputra S; Swan RT; Sen HN; Gordon LK
Ocul Immunol Inflamm; 2020; 28(2):217-227. PubMed ID: 30821569
[No Abstract] [Full Text] [Related]
3. Posterior Uveitis Associated with Cemiplimab.
Dow ER; Hou K; Ransome S; Abbassi S; Tsui E
Ocul Immunol Inflamm; 2022 Jul; 30(5):1211-1213. PubMed ID: 33793370
[TBL] [Abstract][Full Text] [Related]
4. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
6. Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade.
Sun MM; Seleme N; Chen JJ; Zekeridou A; Sechi E; Walsh RD; Beebe JD; Sabbagh O; Mejico LJ; Gratton S; Skidd PM; Bellows DA; Falardeau J; Fraser CL; Cappelen-Smith C; Haines SR; Hassanzadeh B; Seay MD; Subramanian PS; Williams Z; Gordon LK
J Neuroophthalmol; 2021 Dec; 41(4):519-530. PubMed ID: 33136674
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
Fortes BH; Liou H; Dalvin LA
Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
Fan Q; Chen H; Hu Y; Zhao B
Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
[TBL] [Abstract][Full Text] [Related]
9. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis.
Bomze D; Meirson T; Hasan Ali O; Goldman A; Flatz L; Habot-Wilner Z
Ocul Immunol Inflamm; 2022 Jan; 30(1):191-197. PubMed ID: 32749899
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
11. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
12. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.
Dalvin LA; Shields CL; Orloff M; Sato T; Shields JA
Retina; 2018 Jun; 38(6):1063-1078. PubMed ID: 29689030
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in the Treatment of Cancer.
Zam W; Ali L
Curr Rev Clin Exp Pharmacol; 2022; 17(2):103-113. PubMed ID: 33823768
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Omar NE; El-Fass KA; Abushouk AI; Elbaghdady N; Barakat AEM; Noreldin AE; Johar D; Yassin M; Hamad A; Elazzazy S; Dermime S
Front Immunol; 2020; 11():1354. PubMed ID: 33193289
[TBL] [Abstract][Full Text] [Related]
15. Various clinical presentations of uveitis associated with durvalumab treatment.
Vrabic N; Fakin A; Mekjavic PJ; Janzic U; Vrankar M; Valentincic NV
Radiol Oncol; 2022 Apr; 56(2):129-137. PubMed ID: 35412706
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors in Cancer Therapy.
Shiravand Y; Khodadadi F; Kashani SMA; Hosseini-Fard SR; Hosseini S; Sadeghirad H; Ladwa R; O'Byrne K; Kulasinghe A
Curr Oncol; 2022 Apr; 29(5):3044-3060. PubMed ID: 35621637
[TBL] [Abstract][Full Text] [Related]
18. Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency.
Kato K; Mizuno T; Koseki T; Ito Y; Hatano M; Takahashi K; Yamada S; Tsuboi N
In Vivo; 2021; 35(5):2831-2840. PubMed ID: 34410975
[TBL] [Abstract][Full Text] [Related]
19. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
20. Management of immune checkpoint inhibitor-related adverse events: A review of case reports.
Si X; Song P; Ni J; Di M; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Yang X; Wang M; Zhang L
Thorac Cancer; 2020 Mar; 11(3):498-504. PubMed ID: 31970923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]